Synapse - Gastrointestinal Oncology Service

Results (4697)

Treatment of localized esophageal cancer

Journal Article

Brenner, B.; Ilson, D. H.; Minsky, B. D.
Seminars in Oncology (2004)

Novel methodology of response assessment in hepatocellular carcinoma (HCC) - Assessing response by change in tumor enhancement in distinction from conventional means

Meeting Abstract

Wang, L.; Abou-Alfa, G. K.; Liu, F.; Saltz, L. B.; Kalaigian, J.; Zhao, B.; Colville, J.; Nyoro, J.; Schwartz, B.; Schwartz, L.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save

A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F)

Meeting Abstract

Shah, M. A.; Kortmansky, J.; Gonen, M.; Tse, A.; Lefkowitz, R.; Kelsen, D.; Colevas, D.; Winkelman, J.; Yi, S.; Schwartz, G.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save

Response assessment parameters in esophageal cancer - Conventional and novel techniques

Meeting Abstract

Schwartz, L. H.; Colville, J. A. C.; Wang, L.; Hricak, H.; Ilson, D.; Schwartz, G. K.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save

Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803)

Meeting Abstract

Saltz, L. B.; Niedzwiecki, D.; Hollis, D.; Goldberg, R. M.; Hantel, A.; Thomas, J. P.; Fields, A. L. A.; Carver, G.; Mayer, R. J.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save

A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors

Meeting Abstract

Rathkopf, D.; Fornier, M.; Shah, M.; Kortmansky, J.; O'reilly, E.; King, A.; Winkelmann, J.; Kelsen, D. P.; Olsen, S.; Schwartz, G. K.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save

OSI-774 in advanced esophageal cancer: A phase II study

Meeting Abstract

Radovich, D.; Kelsen, D.; Shah, M.; Klimstra, D.; Gavin, S. G.; Munoz, D.; Ilson, D. H.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save

Cardiac toxicity of 5FU: Does prophylactic telemetry monitoring of patients at increased risk for cardiac toxicity improve safety? A 10-year experience

Meeting Abstract

Pizzolato, J.; Baum, M. S.; Steingart, R. M.; Gonen, M.; Minsky, B. D.; Saltz, L. B.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save

A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC)

Meeting Abstract

O'Reilly, E. M.; Abou-Alfa, G. K.; Letourneau, R.; Harker, W. G.; Modiano, M.; Hurwitz, H.; Tchekmedyian, N. S.; Ackerman, J.; De Jager, R. L.; Eckhardt, S. G.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save

A case for time to tumor progression (TTP) as the primary (1 degrees) efficacy endpoint in 1(st)-line metastatic colorectal cancer (MCRC) therapy: Correlation of TTP and overall survival (OS)

Meeting Abstract

Mille, L. L.; Elfring, G. L.; Gruia, G.; Hirawat, S.; Douillard, J. Y.; Saltz, L. B.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save